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ABBREVIATIONS 
AMP, 5' adenosine monophosphate; AMPK, AMP-activated protein kinase; AO, atomic orbital; 
B3LYP,  Becke-3-Lee-Yang-Parr  density  functional;  BG,  biguanide;  BG-H,  deprotonated 
biguanide;  CSD,  Cambridge  Structural  Database;  DFT,  density  functional  theory;  en, 
ethylenediamine;  ESP,  electrostatic  potential;  MO,  molecular  orbital;  Metf,  metformin  N,N-
dimethylbiguanide;  Metf-H,  deprotonated  metformin;  NBO,  natural  bond  orbital;  PDI, 
propanediimidamide; T2D, type 2 diabetes; trien, triethylenetetramine. 
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ABSTRACT 
Metformin (Metf), the most commonly used type 2 diabetes drug, is known to affect the cellular 
housekeeping  of  copper.  Recently  we  discovered  that  the  structurally  closely  related 
propanediimidamide  (PDI)  shows  a  different  cellular  behaviour  than  metformin.  Here  we 
investigate  the  binding  of  these  compounds  to  copper,  to  compare  their  binding  strength. 
Furthermore we take a closer look at the electronic properties of these compounds and their 
copper complexes such as molecular orbital interactions and electrostatic potential surfaces. Our 
results  clearly  show  that  the  copper  binding  energies  cannot  alone  be  the  cause  for  the 
biochemical differentiation between Metf and PDI. We conclude that other factors such as pKa 
values and hydrophilicity of the compounds play a crucial role in their cellular activity. Metf in 
contrast  to  PDI  can  occur  as  an  anion  in  aqueous  medium  at  moderate  pH,  forming  much 
stronger  complexes  particularly  with  Cu
II  ions,  suggesting  that  biguanides  but  not  PDI  may 
induce easy oxidation of Cu
I ions extracted from proteins. The higher hydrophobicity and lack of 
planarity  of  PDI  may  further  differentiate  it  from  biguanides  in  terms  of  their  molecular 
recognition  characteristics.  These  different  properties  could  hold  the  key  to  metformin’s 
mitochondrial activity because they suggest that the drug could act at least in part as a pro-
oxidant of accessible protein-bound Cu
I ions. 
     4 
INTRODUCTION 
It has been estimated that more than 300 million people suffer from the diabetes world-wide.
1 
By 2030 the WHO estimates that diabetes will be the seventh highest cause of death.
2 Type 2 
diabetes  (T2D),  which  covers  around  90%  of  all  diabetes  patients,  is  characterised  by 
hyperglycaemia due to insulin resistance in peripheral tissues. One of the most effective and 
frequently  administered  antihyperglycemic  T2D  drugs  is  metformin  (N,N-dimethylbiguanide, 
Metf; for its chemical structure see Figure 1), which is the first-line treatment because of better 
long-term outcomes compared with other therapies such as insulin secretagogues.
3 It belongs to 
the biguanide family that also include other compounds with antihyperglycemic properties. Metf 
and  other  biguanide  derivatives  have  been  developed  after  it  was  discovered  that  the  blood 
glucose-lowering ingredient in Goat’s Rue is guanidine and other guanidine derivatives such as 
galegine. Synthalin, a diguanide, was developed as a synthetic drug and was more potent and 
showed lower toxicity. However, the liver damage caused by both guanidine and diguanides, 
were a stimulant to search for safer alternatives which led to the development of biguanides as 
T2D drugs.
3 
The exact molecular mechanism of Metf and other T2D drugs remains unclear. One suggested 
mechanism of action is suppression of mitochondrial respiration by inhibition of complex I
4, 5, 
however, the precise mechanism of this inhibition has not yet been established.  
Dysfunctional  copper  metabolism  is  implicated  in  the  development  of  several  diseases. 
6-9 
Mutations in the gene ATP7A results in copper deficiency in most organs, which is the cause of 
Menkes's  disease
10,  11  and  copper  overload  resulting  from  ATP7B  mutation  is  the  cause  of 
Wilson's disease.
12 Dysregulation of copper is also suspected in other diseases, particularly those 
involving protein misfolding
13-15 and in diabetes.
16-20    5 
In our previous study we demonstrated for the first time that the metal-binding properties of 
Metf, particularly towards copper, may be one factor in cell responses to this drug.
21 Metf and 
biguanide  (BG)  show  antihyperglycemic  properties  and  no  free  mitochondrial  Cu
II  could  be 
detected by a Cu
II specific fluorescence probe. In contrast propanediimidamide (PDI) showed no 
antihyperglycemic  effect  and  free  Cu
II  was  detected.  BG  and  Metf  regulate  AMP-activated 
protein  kinase  (AMPK),  whereas  PDI  does  not  have  such  an  effect.  Regulation  of  S6 
phosphorylation is observed for all three compounds. Interestingly, Metf does not lower the 
urinal copper concentration which in T2D patients is raised, whereas triethylenetetramine (trien) 
decreases the urinal copper concentration, but has no antihyperglycemic effect.  
 
FIGURE 1 
 
However, it remained unclear whether Metf binds to Cu
I or Cu
II. In water Cu
II is the more 
stable  oxidation  state.  In  living  organisms  a  complex  machinery  of  cupric  reductase,  a  Cu
I 
specific  membrane  transport  protein,  and  chaperone  proteins  within  the  cells  exist  which 
effectively does not allow free copper ions at cellular level.
22-29 The chaperone proteins play a 
vital role in the copper transport system and are not only abundant in the cell but also in the 
mitochondria. Cu
I is bound to the chaperones by two cysteinates. At the unbound state these 
cysteines are protonated, therefore, a perfectly designed proton array consisting of other amino 
acids is constructed to deprotonate the receiving chaperones or enzymes while simultaneously 
protonating  the  transporter  protein  to  lower  its  copper  binding  affinity.  Moreover,  copper 
metalloenzymes, where the unique copper redox chemistry is needed, are able to bind both Cu
I   6 
and Cu
II. Therefore, there are various possibilities of drug interaction with Cu
I/II proteins and 
Metf could potentially interact with protein bound Cu
I/II ions. 
There  are  major  differences  in  the  coordination  chemistry  of  Cu
I  and  Cu
II.  At  the  lower 
oxidation state Cu
I prefers binding to soft ligands such as thiols, thiolates (cysteine) or thioethers 
(methionine) or sp
2 containing nitrogen (histidine). On the other hand, Cu
II favours binding to 
slightly harder ligands such as amines and imines. According to Pearson’s hard and soft acids 
and  bases  (HSAB)  concept  Cu
I  is  classified  as  a  soft  acid  whereas  Cu
II  is  classified  as  an 
intermediate acid.
30-33 Also Cu
I has 2-4 ligand atoms in the first coordination sphere compared to 
3-6 for Cu
II. Generally a tetrahedral coordination sphere is observed for Cu
I, whereas a square 
planar ligand orientation is commonly found for Cu
II.
34,35 In an enzymatic environment a mixed 
coordination sphere of sulphur and nitrogen containing ligands assist to stabilise Cu
I and at the 
same time facilitates the reversible redox chemistry of Cu
I/II. 
Similar to the imidazole residue in histidine a sp
2 hybridised N1 (for atom labels see Figure 2) 
is the ligand atom for BG, Metf and PDI. This means that π-backbonding can occur and stabilize 
the lower Cu
I oxidation state by transferring electron density into the π-orbitals of the ligands, 
see Figure 3. This type of molecular orbital (MO) interaction may also be important for Cu
II as 
its 3d-orbitals are almost filled up. The methylene CH2 moiety in PDI compared to the secondary 
amine N2 in BG and Metf causes a disruption of the π-system, whereas the lone-pair of N2 can 
contribute electron density into the adjacent carbon pz-orbital in BG and Metf, which results in a 
planar molecular structure for the latter ones and a non planar geometry for PDI in the complex. 
This is similar to the stabilisation effect detected in peptide bonds. 
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FIGURE 3 
 
Additionally, the N2-H group contains a protic hydrogen whereas the methylene hydrogens 
cannot undergo proton exchange in aqueous media. Deprotonated metal complexes of PDI are 
known, however, those are synthesised in non-protic solvents under conditions that avoid any 
water contamination.
36-38 Due to the protic hydrogen the most stable neutral form of BG and Metf 
in water is a tautomer in which the N2-H proton is formally transferred to N1 or N3.
39 This leads 
to a fully conjugated π-system in the ligands. However, only the N2 can then act as a donor atom 
as has been observed with a similar ligand in a known Ag
I complex.
40 
Biguanides formally belong to the 1,3,5-triazapentadienyl
41, 42 (also known as imidoylamidine) 
ligand  family  and  PDI  is  a  member  of  the  1,5-diazapentadienyl
35,  38,  43  (also  known  as  β-
diketiminate)  ligand  class  which  are  well  established  as  metal  ion  ligands  in  inorganic 
coordination  chemistry.  However,  their  structure  and  chemistry  is  mainly  established  in 
nonaqueous  solvents,  hence,  their  properties  cannot  be  transferred  directly  to  aqueous 
environments particularly biosystems with very sensitive pH range. 
The protonation equilibria of BG have been studied along with complex formation with Cu
II at 
a  pH  range  of  2-12.
44,  45  Firstly,  BG  predominately  exists  in  an  equilibrium  between  its 
monoprotonated and neutral form at physiological pH and no deprotonated BG-H was reported 
for the given pH range. Secondly, the formation of [Cu
II(OH)(BG)]
+ was observed to be the 
major Cu-BG complex, however, binary Cu
II-BG complexes such as [Cu(BG)2]
2+, [Cu(BG)(BG-
H)]
+ and [Cu(BG-H)2]
0 were also observed at slightly higher pH values. The pKa value of 6.88 
was reported for [Cu(OH)(BG)]
+ hence indicating the possibility of deprotonated BG while being   8 
coordinated to Cu
II. Neither Metf nor PDI have been studied in this detail. However, these results 
are at least qualitatively transferable to Metf. 
In  a  recent  study  the  antimicrobial  properties  of  binary  metformin  metal  complexes  were 
studied.
46,47  Among  other  physico-chemical  properties  the  cyclic  voltammogram  of 
[Cu
II(Metf)2]
2+  was  measured  against  a  Ag/AgCl  electrode  and  showed  a  reduction  peak  at 
320mV and oxidation peak at 490mV giving a E1/2 of +405 mV which is in the range of the 
reduction potentials of copper containing enzymes.
48 
Here we aim to build upon our previous work on the cellular response to T2D drugs and in 
particular on the observed variations of free copper levels after drug treatment. We gain deeper 
insight into the copper binding properties of BG and Metf with focus on possible differences to 
PDI, which may be important for their different biological antihyperglycemic properties. We 
compute binding energies and compare the optimized structures to known crystal structures, in 
the process benchmarking the computational methodology for such systems.  Furthermore we 
will investigate the electronic properties such as molecular orbitals and electrostatic potentials of 
these molecules. 
 
MATERIALS AND METHODS 
Computational Details 
Geometries of all the computed structures were obtained by optimization with B3LYP
49-53. The 
basis set Def2-TZVPD
54 was used for all atoms. For Cu(I) complexes singlet spin-multiplicity 
was used, while for Cu(II) doublet spin-multiplicity was used.  For the open-shell species spin-
contamination was found to be negligible. Each structure was veriﬁed to be a minimum by the 
absence of imaginary frequencies in the vibrational analysis. The calculations were performed   9 
using Gaussian 09 A.02 and C.01
55. We also tested other DFT functionals including BP86
51, 56, 
M06
57  and  M06L
58  which  showed  no  significant  difference  to  B3LYP.  Natural  bond 
orbital (NBO) charges were calculated with the integrated NBO 3.1
59 within Gaussian 09. 
 
RESULTS 
A. Comparision of X-ray Structures and Computed Complexes 
Several crystal structures are known for bisbiguanide-copper complexes. Three describe the 
[Cu(BG)2]
2+ complex and contain different counterions.
60-62 Although these complexes are planar 
they are not symmetric in terms of their bond lengths. An average over all three structures is 
presented in Table 1 and will be discussed here in comparison to the DFT optimized structure. 
One  structure  for  the  neutral  complex  Cu(BG-H)2
63  has  been  published  which  contains  the 
deprotonated biguanide (BG-H). The deprotonation was confirmed by visual inspection of H-
bond contacts to the deprotonated N2(-). 
The observed Cu-N1 bond length 1.944 Å is in the normal range of Cu
II-N ligand bonds. The 
computed Cu-N bond distance 1.980 Å is slightly longer, however, this is expected and is a 
known effect when computing complexes in gas phase and comparing them to crystal structures. 
Also the Cu-N bond length in the different crystal structures can vary from 1.921 Å to 1.958 Å 
for  complexes  with  the  neutral  BG  ligand.  The  most  symmetrical,  coplanar  X-ray  structure 
COBMAH
61  is  Ci  symmetric  with  Cu-N  distances  of  1.933  and  1.939  Å.  This  feature  is 
reproduced by the DFT calculation with slightly different Cu-N bonds of 1.978 and 1.982 Å. 
Interestingly, the computed minimum structure is slightly twisted and has C2 symmetry with 
regards to the heavy atoms which is abolished by the non-planar H-atoms of the amine groups.   10 
The coplanar, D2h symmetrical geometry is in fact computed to be a rotational transition state in 
the gas phase with a negligible barrier of ΔE
‡ 1.04 and ΔG
‡ 3.65 kcal/mol.  
The observed N1-C1 bond length (X-rayav: 1.292 Å; DFT: 1.299 Å) is slightly longer than a 
pure C-N double bond and whereas the C1-N2 (X-rayav: 1.373 Å; DFT: 1.383 Å) and C1-N3 (X-
rayav:  1.343  Å;  DFT:  1.344  Å)  are  much  shorter  than  a  C-N  single  bond,  which  indicates 
conjugation of the N2-lone pairs into the N1-C1 double bound. The computed N-C bonds are in 
much better agreement with the crystal structure compared to the metal-ligand bond because 
these bonds are less affected by crystal packing. Particularly the changes upon deprotonation of 
the secondary amine N2-H in the N1-C1 and C1-N2 bonds which indicate a delocalization of the 
negative charge within the ligand bonds that form the metallacycle is very well reproduced in the 
computed structure. The observed differences between the different X-ray structures are possibly 
explained by the different counter ions. Remarkably, an almost negligible shortening of -0.002 Å 
for the Cu-N bond length is observed for the neutral complex Cu(BG-H)2
63 compared to the 
average of the cationic complexes, whereas the DFT calculations reveal a stronger reduction of -
0.009 Å indicating a much larger increase in the Cu-N bond strength than the experimental 
results are suggesting.  
 
TABLE 1 
 
Moving on to the Metf-Cu complexes, in total five crystal structures are known, see Table 2, 
three include the neutral Metf
47, 64, 65 and two the deprotonated metformin (Metf-H)
64, 
65 with Cu
II. 
Some differences compared to the BG-Cu complexes in the bond distances can be observed 
which are due to the methyl groups that abolish the symmetry of the BG complex. The N1-C1   11 
bond becomes slightly longer (X-rayav: 1.305 Å; DFT: 1.307 Å) and the N1’-C1’ slightly shorter 
(X-rayav:  1.276  Å;  DFT:  1.298  Å)  compared  to  the  N1-C1  bond  (X-rayav:  1.291  Å;  DFT: 
1.299 Å) in the BG complex. This alteration is also observed in the computed complex, although 
the decrease in the N1’-C1’ bond is only marginal. The asymmetrical nature of the ligand is also 
noticeable in different Cu-N bond distances of Cu-N1 1.942 Å and Cu-N1' 1.929 Å, surprisingly 
the DFT computed Cu-N bond distances show an opposite trend with 1.973 Å and 1.980 Å, 
which might be due to crystal packing effects compared to the gas-phase computed, single-
molecule structure. However, the other bond distances are in excellent agreement.  
The two crystal structures Cu
II(Metf-H)2·H2O (ETOFOI)
65 and Cu(Metf-H)2·8H2O (EFIXUM)
64 
were  synthesized  under  basic  conditions.  The  ETOFOI  structure  complex  contains  two 
Cu
II(Metf-H)2  molecules  in  the  unit  cell  with  ETOFOI-A  resembling  the  Cu
II(BG-H)2  more 
closely than ETOFOI-B and EFIXUM. The best agreement with the DFT optimized Cu(Metf-H)2 
structure  is  also  with  ETOFOI-A.  The  lengthened  N1-C1  and  N1’-C1’  double  bond  is 
particularly well reproduced by the B3LYP optimized structure.  
Surprisingly, in EFIXUM and ETOFOI-B hardly any increase in the N1-C1 bond and decrease 
in the C1-N2 bond is observed, which most likely is due to strong H-bonding of crystal water in 
the proximity of N2. Two crystal waters are close two N2(-) in EFIXUM at a distance of 2.86 Å 
and 2.91 Å (N2-O distance), whereas one water is found in ETOFOI-B to be 2.84 Å away from 
N2(-). 
Overall, the crystal structures of the neutral complex Cu
II(Metf-H)2 indicate the possibility of 
the formation of stable Cu
II complex with deprotonated metformin at basic conditions. 
 
TABLE 2   12 
 
Only one crystal structure for the homoleptic PDI complex is known.
66 The Cu-N bond 1.956 
Å in the [Cu
II(PDI)2]
2+ complex is slightly longer than in the BG complex 1.943 Å, which is also 
observed  in  the  computed  structure  with  1.999  Å  compared  to  1.980  Å,  for  PDI  and  BG 
respectively. In contrast to the BG complexes the C1-C2 bond (1.501 Å) in the PDI complex is 
much longer compared to the C1-N2 bond (1.373 Å) in [Cu
II(BG)2]
2+ and closer to a pure single 
C-C bond than a double bond.  
Intrigued by this long C1-C2 bond we calculated the rotational barrier of the free, neutral 
ligand of 2.42 kcal/mol for PDI and 18.20 kcal/mol for BG. The much higher rotational barrier 
for BG gives an indication about the strength of the conjugation of the N2 lone pair into the 
adjacent N1-C1 double bond. 
 
TABLE 3 
 
B. Binding Energies of Cu
I/II Complexes 
The binding energies that are presented in Table 2 were computed in two different ways. The 
interaction energy ΔEint corresponds to the binding energy of the Cu-centre or CuOH fragment 
with the ligand in its geometry found in the optimized complex structure. On the other hand, the 
binding free energy ΔG is determined using the lowest energy tautomer and conformer of the 
ligands. The negative ΔG is equal to the dissociation energy De. The difference between the 
energy of the ligand in its complex geometry and its lowest tautomer and conformer is called 
preparation energy ΔEprep.   13 
We have computed binding energies for Cu
I and Cu
II complexes of the mono-L complexes, the 
homoleptic, bis-L complexes and the mixed [Cu
I/II(OH)(L)]
0/+ complexes. The latter is particular 
important in aqueous media as this is the major Cu
II-BG species at physiological pH in most 
biological compartments. We also calculated the complexes with deprotonated ligands as this 
might  become  important  at  higher  physiological  pH,  occurring  for  example  inside  the 
mitochondria. 
 
TABLE 4 
 
Firstly, the [Cu
I/II(L)]
+/2+ complexes are discussed. Among all ligands Metf shows the strongest 
interaction energy with Cu
I, however, due to lower ΔEprep PDI forms the strongest [Cu
I(L)]
+ 
complex. Interestingly, for BG and PDI ΔEint is almost equal. En binds around 25-30 kcal/mol 
weaker to Cu
I compared to the other ligands, but De is only 6-16 kcal weaker, which as well is 
due to a small preparation energy. The weaker binding of en is due to the lack of π-backbonding, 
and also larger steric strain as en forms a 5-membered metallacycle compared to the 6-membered 
metallacycle of the BG, Metf and PDI-Cu complexes. 
 
FIGURE 4 
 
The Cu
II complexes for BG, Metf and PDI are more than 200 kcal/mol more stable than the Cu
I 
complex which is due to stronger Coulomb and orbital interactions. Whereas the en complex 
does not receive as strong a stabilisation compared to the other ligands. This could be due to two 
factors, the σ-bonding with the N lone pair is smaller in the sp
3 hybrid N compared to the slightly   14 
larger sp
2 hybid lone pair with more s-character. The other factor, although this plays a minor 
role, is the possibility of the occupied ligand π-orbitals donating electron density towards the Cu-
d
9 center. Overall, Metf binds strongest, however, the De of PDI is only 3.4 kcal/mol lower. 
Secondly, we will consider the homoleptic [Cu
I/II(L)2]
+/2+ complexes. For BG, Metf and PDI 
complexes  we  observe  similar  trends  as  in  the  mono-complexes,  with  an  even  stronger 
stabilisation for PDI compared to BG and Metf due to a much larger ΔEprep for the latter ones. We 
also  include  trien  in  this  group  of  complexes.  Obviously  due  to  its  tetradentate,  chelating 
properties it surpasses BG, Metf and PDI at equal molarity, however, we are more interested in 
its binding properties in comparison to copper-ligand complexes with a saturated copper ligand 
sphere. Trien has almost the same ΔEint than en, but a larger De due to entropic effects by 5 
kcal/mol with Cu
I and by ~10 kcal/mol with Cu
II which agrees with the experimentally observed 
stronger stabilisation of trien with Cu
II. 
Next  we  will  investigate  the  binding  of  BG,  Metf,  PDI  and  en  in  a  mixed  complex  with 
Cu(OH), where OH is a stronger ligand than the neutral, bidentate ligands. The Cu
I cation  forms 
a strong bond with the hydroxide anion, which results in weak binding of a second, non-anionic 
ligand. Here we observe a surprising order for the Cu
I complexes, PDI forms the strongest mixed 
complexes, en follows as the second strongest, then BG and Metf forms the weakest complex. 
The differences between the ligands is again mainly due to the larger ΔEprep for BG and Metf 
compared to low ΔEprep for PDI and en. 
The mixed Cu
II(OH)(L) complexes are slightly stronger than the Cu
I(L) complexes, with very 
similar trends and similar stabilities for BG, Metf and PDI. 
In addition to the complexes with neutral ligands we have also calculated the binding energies 
for the deprotonated BG-H, Metf-H and PDI-H. It is important to point out here that at higher pH   15 
BG and Metf can be deprotonated in aqueous medium, whereas PDI, even when in a metal 
complex which lowers its pKa, will only be deprotonated above pH 14 in non-aqueous medium 
as the methylene group in PDI cannot be deprotonated by bases in aqueous media. 
These anionic ligands bind much stronger than the neutral counterparts as they have much 
larger ionic bonding contributions than the neutral ligands. Also the Cu
II complexes receive an 
even  stronger  stabilization  than  the  Cu
I  complexes.  This  could  indicate  an  easier  oxidation 
compared  to  the  neutral  ligands  when  a  Cu
I  ion  is  extracted  from  a  protein  by  Metf-H.  In 
addition, these deprotonated forms of the biguanides alone might be a strong enough ligand to 
extract  Cu
I  from  proteins  with  thiolate  ligands.  This  modelling  indicates  that  any  copper-
dependent effects of the drug may be restricted to or most prominent in the mitochondria and 
other compartments in the body where physiological pH is above the typical range, allowing 
deprotonation of the drug. Such pH-dependent activation or priming could potentially explain 
why metformin is almost invariably found in the biological literature to act on the mitochondria, 
with very few effects reported in other cellular compartments.  
 
C. Electronic Properties 
To gain a deeper understanding about the biguanide type ligands compared to the PDI we take 
a look at the molecular orbitals (MO) of these ligands in their geometry in a complex, see Figure 
4. For simplicity we will concentrate on the π-orbitals and the MOs with the N1 lone pairs.  
The lowest lying MOs with π-character in BG and PDI are the MO-19. PDI, which is not 
planar, still shows a π-like plane with one σ-C2-H bond above and the other σ-C2-H bond 
mixing with the N1-C1 double bond plus contribution from the N3 lone pairs. The MO-19 in BG 
is a mix of π and σ character. The lone pairs of N2 and N3 are mixing with the pz AO of the sp
2   16 
hybridized C1, plus σ-character from the N1-H bond. For BG the MO-21 looks very similar to 
the MO-19 with σ- and π-character, except that it is the negative combination of the AOs and 
therefore higher in energy. The MO-21 in PDI only shows σ-character, which explains the much 
lower rotational barrier for PDI compared to BG. The MO-22 is basically the same for both 
molecules. MO-23 in BG is a pure combination of N2 and N3 lone pairs, whereas in PDI as there 
is no lone pair on C2 this MO is a mix of π-MO with contributions from the N1-C1 double bonds 
and  the  N3  lone  pairs  plus  out-of  plane  C2-H  σ-bond  character.  MO-24  is  the  positive 
combination of the N1 lone pairs which is responsible for bonding to the empty 4s AO of Cu. 
The next two MOs 25 and 26 are identical for BG and PDI and are pure π-MOs. The HOMO, 
MO-27, is the negative combination of the N1 lone pairs and donate electron density into the 
empty 4p AO of Cu. These MOs show that the electron density on N1 is very similar in BG and 
PDI which explains the strong similarities in the observed binding energies for these ligands with 
Cu. 
To emphasise this point we calculated the NBO charges for the [Cu(L)]
2+ complexes, Table 3. 
The charge on Cu decreases from +1.87, +1.84 to +1.80 for BG, PDI and en, respectively. This is 
coincident with decreasing negative charge on the ligand nitrogens N1 of these ligands from -
0.87, -0.84 to -0.80.  Figure 2 illustrates the possible orbital interactions for the sp
2-type N in BG, 
Metf and PDI compared to the sp
3-type N in en and trien. The former ones are capable of 
stronger bonds due to σ-donation while at the same time receiving electron density from the 
metal  centre  via  π-backdonation,  these  two  types  of  bonding  have  a  synergistic  effect  and 
reinforce each other. On the other hand the pure σ-donor ligands en and trien cannot accept 
electron density in π-MOs, which results in weaker binding. The small difference between BG   17 
and PDI can either be due to slightly larger σ-donation or smaller π-backdonation in PDI or a 
combination of both. 
 
TABLE 5 
 
D. ESP Maps 
The electrostatic potential (ESP) maps for BG and PDI in their neutral forms are presented in 
Figure 5. Interestingly, the PDI-A shows a slightly more negative potential around the N1 atoms 
which will form coordination bonds toward Cu. This means that PDI is a slightly stronger Lewis 
base than BG-A and is consistent with our findings that the PDI has a larger ΔEint. It has to be 
pointed out here that the presented structure PDI-A is not a minimum structure and therefore not 
stable in nature; however, this is the conformation that will bind to a metal center in a bidentate 
binding mode. BG-A on the other hand is a minimum structure, which also is in one sense 
surprising as the two N1 lone pairs should strongly repel each other, however, it seems that the 
p-stabilisation as shown by the MOs exceeds the steric repulsion. Also the methylene moiety 
causes a greater part of PDI-A to be hydrophobic compared to BG-A, which could be important 
in terms of molecular recognition when binding to a Cu centre of a protein. Therefore, not only 
does PDI cause greater steric hindrance due to its lack of planarity but also introduces repulsive 
or at least weaker interactions with H-bond acceptors. 
 
FIGURE 5 
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The PDI-B represents the lowest energy conformer of the neutral PDI. An internal H-bond in 
PDI-B results in a very weak hydrophilicity, with strong, large areas that can be described as 
lipophilic. In contrast the BG-B, which is not the lowest tautomer of BG, shows much more 
pronounced negative and positive moieties which results in stronger H-bond donor and acceptor 
properties  than  PDI-B.  This  is  suggestive  evidence  that  PDI  may  be  able  to  penetrate  cell 
membranes, whereas BG and Metf need to be taken up via transmembrane transporters. 
The lowest energy conformer and tautomer of BG-C does not show as strong Lewis acid or 
basic  sites  compared  to  BG-B,  however,  there  are  also  fewer  hydrophobic  areas  above  the 
molecules plane which means that solvation and stabilisation due to H-bonding can be stronger 
not only on the edges of the molecules but also along the molecular plane. 
 
 
DISCUSSION 
In  the  presented  study  we  find  that  the  biologically  observed  differences  between  neutral 
biguanide  compounds  (BG  and  Metf)  and  PDI  cannot  be  explained  by  different  Cu-binding 
energies. These ligands are electronically too similar and the substitution of the secondary amine 
to methylene has no negative effect on the complex formation via the N1 nitrogens for PDI. 
However, the secondary amine of biguanides can be deprotonated in aqueous medium as the pKa 
value is reduced when BG or Metf are coordinated to Cu
I/II. These anions form much stronger 
complexes compared to their neutral form. It is known that the mitochondrial matrix pH is higher 
than normal cellular or serum pH. Inside the mitochondria it is possible that the equilibrium is 
shifted towards the Cu
I/II(Metf-H) complex. Extraction of Cu
I ions from proteins is possible and 
subsequent oxidation to Cu
II would remove the redox active Cu
I ions from the mitochondria. This   19 
suggests that metformin could act in cells at least in part as a copper-binding prodrug, becoming 
activated  by  elevated  mitochondrial  pH.  This  is  consistent  with  the  strong  emphasis  on 
mitochondrial  effects  of  this  drug  in  the  biological  literature.  In  addition,  this  explains  the 
differences between mitochondrial responses to metformin and PDI, as the latter agent only 
becomes deprotonated at much higher pH. There is a possibility that high binding affinities of 
Metf-H  to  copper  could  significantly  affect  the  mitochondrial  copper  pool,  which  would 
probably have an impact on metal homeostasis of other metals and lead to mis-metallation of 
important metalloproteins.
67 Redox properties of such copper complexes may interfere with the 
sensitive redox chemistries occurring inside the cell, such as the mitochondrial electron transport 
chain.  
Furthermore,  ESP  maps  show  that  molecular  recognition  processes,  which  are  copper-
independent, could play a vital role in explaining the different drug properties of biguanides and 
PDI.  Further  work  will  establish  if  the  much  stronger  hydrophilicity  of  BG  facilitates  its 
mitochondrial activity. On the other hand, we showed higher lipophilicity of PDI, which might 
enable it to penetrate cell membranes without relying on membrane transport proteins. 
In summary, these calculations clearly demonstrate that metformin is a pH-sensitive copper-
binding agent with a pKa within the physiological pH range and a strongly hydrophilic character. 
Together, these properties of metformin distinguish it from the other copper-binding agents we 
have studied and they are also likely to account for many of the biological/therapeutic responses 
to the drug. 
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FIGURES 
 
 
 
Figure 1. Compounds used as ligands 
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Figure 2. Numbering of atoms in X-ray and computed structures. 
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Figure 3. Schematic representation of possible orbital interactions Cu complexes with BG, Metf 
and PDI (A) and with en and trien (B) 
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Figure 4. Molecular orbitals for BG and PDI   34 
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Figure 5. Electrostatic potential maps for BG and PDI. Red negative, green neutral and blue 
positive ESP values.   35 
TABLES.  
 
Table 1. Comparison of critical bonds
† (distance in Ångström) of [Cu
II(BG)2]X1,2 (X= CO3
2¯, Cl¯, 
[Cu
II(C5H7O2)(Cl)]¯)  and  Cu
II(BG-H)2  crystal  structures  and  computed  [Cu
II(BG/BG-H)2]
2+/0 
complexes. 
BG  CSD code  X  Cu-N  N1-C1  C1-N2  C1-N3 
X-ray  BGCUCB
60   CO3
2 ¯  1.951  1.296  1.374  1.351 
  COBMAH
61  [Cu
II(C5H7O2)(Cl)]
 ¯  1.936  1.287  1.372  1.337 
  ZZZDZQ01
62  Cl
 ¯  1.941  1.289  1.373  1.342 
  Ø
‡([Cu(BG)2]
2+    1.944  1.292  1.373  1.344 
  STD    0.011  0.009  0.009  0.012 
  MUE    0.023  0.016  0.017  0.018 
B3LYP  [Cu(BG)2]
2+    1.980  1.299  1.383  1.344 
X-ray  SAPFUL
63   —  1.941  1.320  1.355  1.360 
B3LYP  Cu(BG-H)2    1.971  1.318  1.337  1.383 
 
†Experimental  bond  lengths  are  averaged  for  each  crystal  structure  (BGCUCB  C1-
symmetry, COBMAH Ci symmetry and ZZZDZQ01 C1 symmetry. 
‡Average of all 
[Cu
II(BG)2]X1,2 structures. 
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Table 2. Comparison of critical bond
† (distance in Ångström) of [Cu
II(Metf)2]X1,2 (X= ClO4¯, CO3
2¯, Cl¯)  
and Cu
II(Metf-H)2 crystal structures and computed complexes. 
Metf  CSD code  X  Cu-N1  Cu-N1'  N1-C1  N1'-C1'  C1-N2  C1'-N2  C1-N3  C1'-N3' 
X-ray  AJUHUJ
47  ClO4¯  1.944  1.944  1.303  1.268  1.374  1.384  1.354  1.344 
  HIBPOX
68  CO3
2 ¯  1.931  1.920  1.305  1.282  1.364  1.393  1.342  1.322 
  HIHDUX
69  Cl
 ¯  1.948  1.931  1.307  1.279  1.377  1.379  1.342  1.344 
  Ø([Cu(Metf)2]
2+)    1.941  1.932  1.305  1.276  1.372  1.385  1.346  1.337 
  STD    0.009  0.012  0.002  0.007  0.007  0.007  0.007  0.013 
  MUE    0.010  0.012  0.002  0.008  0.008  0.008  0.008  0.015 
B3LYP  [Cu(Metf)2]
2+    1.973  1.980  1.307  1.298  1.389  1.379  1.346  1.348 
X-ray  EFIXUM
64  —  1.943  1.921  1.312  1.306  1.372  1.350  1.365  1.386 
  ETOFOI
65-A
†  —  1.938  1.928  1.324  1.320  1.358  1.350  1.368  1.371 
  ETOFOI
65-B
†  —! 1.950! 1.923! 1.315! 1.310! 1.371! 1.342! 1.357! 1.391!
  Ø(Cu(Metf-H)2)    1.944  1.924  1.317  1.312  1.367  1.347  1.363  1.383 
  STD    0.006  0.004  0.006  0.007  0.008  0.005  0.006  0.010 
  MUE    0.006  0.004  0.007  0.008  0.009  0.005  0.006  0.012 
B3LYP  Cu(Metf-H)2    1.970  1.967  1.323  1.320  1.343  1.332  1.383  1.388 
 
†The unit cell of ETOFOI contains two Cu(Metf-H)2 molecules. 
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Table 3. Comparison of critical structural parameters (bond distance in Ångström, angle 
in  degrees)  of  [Cu
II(PDI)2][ClO4]2  crystal  structures  and  computed  [Cu
II(PDI/PDI-
H)2]
2+/0 complexes. 
PDI  CSD code  X  Cu-N  N1-C1  C1-C2  C1-N3  ∠N1-N2-C3-C2
† 
X-ray  MALDOU
66   ClO4¯  1.956  1.288  1.501  1.332  21.6 
B3LYP  [Cu(PDI)2]
2+    1.999  1.297  1.514  1.336  22.1 
  [Cu(PDI-H)2]
0    1.976  1.321  1.403  1.394  1.4 
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Table 4. Binding energies of Cu complexes. B3LYP/Def2-TZVPD. Energies in kcal/mol. 
      BG  Metf  PDI  en  trien 
 [Cu
I(L)]
+  ΔEint  -119.77  -125.07  -120.74  -95.15   
   ΔG (=-De)  -84.71  -87.45  -94.18  -78.60   
 [Cu
II(L)]
2+  ΔEint  -331.77  -347.81  -332.66 -270.92   
   ΔG (=-De)  -286.23  -299.91  -296.49 -250.70   
              
 [Cu
I(L)2]
+  ΔEint  -183.80  -187.80  -186.28 -154.32 -151.04 
   ΔG (=-De)  -105.97  -106.64  -124.85 -112.52 -117.58 
 [Cu
II(L)2]
2+  ΔEint  -489.52  -505.09  -488.51 -410.06 -409.90 
   ΔG (=-De)  -391.59  -402.19  -405.96 -355.32 -364.10 
              
 [Cu
I(OH)(L)]  ΔEint  -50.88  -47.80  -51.05  -42.10   
   ΔG (=-De)  -16.26  -12.02  -34.12  -24.60   
 [Cu
II(OH)(L)]
+ ΔEint  -138.25  -144.61  -138.73 -112.33   
   ΔG (=-De)  -97.37  -101.23  -105.93  -88.99   
              
 [Cu
I(L-H)]  ΔEint  -229.86  -231.38  -234.86     
   ΔG (=-De)  -200.71  -201.60  -203.80     
 [Cu
II(L-H)]
 +  ΔEint  -555.26  -561.38  -566.70       39 
   ΔG (=-De)  -511.20  -518.40  -530.24     
              
 [Cu
I(L-H)2]¯  ΔEint  -353.80  -351.71  -359.31     
   ΔG (=-De)  -220.55  -220.70  -218.21     
 [Cu
II(L-H)2]  ΔEint  -836.32  -837.06  -846.10     
   ΔG (=-De)  -678.65  -680.45  -680.12     
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Table 5. NBO charges for [Cu
II(L)]
2+, L=BG, PDI and en. 
  BG  PDI  EN   
Cu
II +1.38  +1.34'+1.30'  
N1  )0.87' )0.84' )0.80'  
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